Piper Sandler analyst Matt O’Brien lowered the firm’s price target on Medtronic (MDT) to $91 from $105 and keeps a Neutral rating on the shares. The firm is updating its Medtronic model to align with the company’s updated EPS guidance following the divestiture of the diabetes business.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDT:
- Edwards Lifesciences upgraded to Outperform from Peer Perform at Wolfe Research
- Medtronic price target raised to $120 from $118 at Barclays
- MiniMed initiated with a Buy at BofA
- Medtronic announces FDA clearance of Stealth AXiS surgical system
- Medtronic: Temporary MiniMed Charge Leaves Multi‑Year Earnings Growth and Buy Thesis Intact